Active substance Semaglutide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension
Main indication Other metabolism and Endocrinology
Extended indication Obesitas bij volwassenen


Proprietary name Ozempic
Manufacturer Novo Nordisk
Mechanism of action GLP-1 receptor agonist
Route of administration Subcutaneous
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)


Registration route Centralised (EMA)
Submission date 2021
Expected Registration February 2022
Orphan drug No
Registration phase Clinical trials
Additional comments De fabrikant verwacht registratie in februari 2022.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost 1,400.00
Additional comments Voor Ozempic: 13 pennen semaglutide (4 toedieningen van 0,5 mg) kosten in totaal €1.433,53. De prijs voor een pen met hogere dosis is gelijk. Kosten mogelijk vergelijkbaar voor orale tabletten.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.